Live Analysis: Fate Therapeutics, Inc. (FATE) is showing promising performance today with a price of $1.32, up by 1.5 cents (1.15%) from the previous close. The trading volume is noteworthy at $326,357, which is 21.96% higher than the average.
Earnings Overview: FATE's latest quarterly earnings report on Tuesday, March 3rd, revealed a consensus estimated EPS of -0.27.
Cash Flow: FATE's cash flow indicates a positive net change in cash of $6 million, with operating cash flow at -$23.31 million and free cash flow at -$24.51 million.
Income Statement: The company reported revenue of $1.37 million, gross profit at -$11.53 million, and an operating income of -$34.72 million. Notably, the net income stands at -$32.37 million.
Ratios: Key ratios depict a quick ratio of 5.79, return on assets at -10.15, and a debt ratio of 24.41. The price to book ratio is 0.56, while the price to sales ratio is 85.26.
Balance Sheet: FATE's balance sheet shows total assets of $318.94 million, total liabilities of $111.75 million, and net debt of $31.22 million.
This comprehensive financial snapshot underscores FATE's resilience and positive trajectory in the current market session.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.